Genetic testing in ovarian cancer – clinical impact and current practices

References

[1] Andt V, Feller A, Hauri D, Heusser R, Junker C, Kuehni C, et al. Cancer in Switzerland 2011–2015 (Schweizerischer Krebsbericht 2015,) Swiss Federal Statistical Office (Bundesamt für Statistik), Neuchâtel, 2016.Search in Google Scholar

[2] Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed ovarian carcinoma: ESMO Clinical Practice Guidelines for Diagnostics, Treatment and Follow-Up. Ann Oncol. 2013;24(6):vi24–vi32.10.1093/annonc/mdt333Search in Google Scholar PubMed

[3] Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality. J Am Med Assoc. 2011;305:2295.10.1001/jama.2011.766Search in Google Scholar PubMed

[4] National Academies of Sciences, Engineering and Medecine. Ovarian Cancers: Evolving paradigms in research and care. 2016.Search in Google Scholar

[5] Survival Rates for Ovarian Cancer, by Stage. https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html. Accessed April 6, 2019.Search in Google Scholar

[6] Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108:18032–7.10.1073/pnas.1115052108Search in Google Scholar PubMed PubMed Central

[7] Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Am Med Assoc. 2017;317:2402–16.10.1001/jama.2017.7112Search in Google Scholar PubMed

[8] Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008;14:3761–7.10.1158/1078-0432.CCR-07-4806Search in Google Scholar PubMed

[9] Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. J Am Med Assoc Oncol. 2016;2:482–90.10.1001/jamaoncol.2015.5495Search in Google Scholar PubMed PubMed Central

[10] Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654–63.10.1200/JCO.2011.39.8545Search in Google Scholar PubMed PubMed Central

[11] Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547–53.10.1200/JCO.2013.53.2820Search in Google Scholar PubMed PubMed Central

[12] Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Consortium of Investigators of Modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134–47.10.1158/1055-9965.EPI-11-0775Search in Google Scholar PubMed PubMed Central

[13] Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017;217:334.e1–e9.10.1016/j.ajog.2017.05.036Search in Google Scholar PubMed

[14] Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. kConFab Investigators; Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. J Am Med Assoc. 2012;307:382–90.10.1001/jama.2012.20Search in Google Scholar

[15] Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20:764–75.10.1158/1078-0432.CCR-13-2287Search in Google Scholar

[16] Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, Del Campo JM, et al. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecol Oncol. 2016;140:443–9.10.1016/j.ygyno.2015.12.027Search in Google Scholar

[17] Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.10.1056/NEJMoa1105535Search in Google Scholar

[18] Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving Olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17:1579–89.10.1016/S1470-2045(16)30376-XSearch in Google Scholar

[19] Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852–61.10.1097/OGX.0000000000000107Search in Google Scholar

[20] Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.10.1016/S1470-2045(17)30469-2Search in Google Scholar

[21] Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.10.1016/S0140-6736(17)32440-6Search in Google Scholar

[22] Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–64.10.1056/NEJMoa1611310Search in Google Scholar PubMed

[23] Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.10.1056/NEJMoa1104390Search in Google Scholar PubMed

[24] Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.10.1056/NEJMoa1103799Search in Google Scholar

[25] Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–505.10.1056/NEJMoa1810858Search in Google Scholar

[26] LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15–28.10.1016/S1470-2045(18)30786-1Search in Google Scholar

[27] Pilié PG, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25:3759–71.10.1158/1078-0432.CCR-18-0968Search in Google Scholar PubMed

[28] Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake 2nd DD, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570–6.10.1200/JCO.2009.27.2997Search in Google Scholar PubMed PubMed Central

[29] Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.10.1038/nature10166Search in Google Scholar PubMed PubMed Central

[30] Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, et al. Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017;145:130–6.10.1016/j.ygyno.2017.01.030Search in Google Scholar PubMed